GLP-1 Market
LLY $1164.89 ▲ +1.0% NVO $39.80 ▼ -8.0% PFE $27.74 ▲ +0.3% VKTX $30.11 ▲ +3.9% KLRA $11.99 ▼ -6.5% GPCR $36.81 ▲ +5.2% RHHBY $55.30 ▲ +2.1%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Epalrestat

Company
Haibo Shao
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 22, 2026

Find a Clinical Trial Near Me

See recruiting studies for Epalrestat and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06201611

    Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.

    Not yet reported, Not yet reported St. John's Research Institute 120 participants Est. completion 2026-03-30 2 sites
    Other conditions: Diabetic Neuropathy Peripheral
    View official trial listing →
  • Terminated NCT NCT03244358

    Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

    Not yet reported Sun Yat-sen University 12 participants Est. completion 2020-12-01 1 site Stand-alone
    Other conditions: Triple Negative Breast Cancer
    View official trial listing →
  • Terminated NCT NCT04925960

    Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

    Not yet reported Maggie's Pearl, LLC 42 participants Est. completion 2025-02-28 1 site Stand-alone
    Other conditions: Pmm2-CDG, Phosphomannomutase 2 Deficiency, Phosphomannomutase 2 Congenital Disorder of Glycosylation, Phosphomannomutase II Congenital Disorder of Glycosylation, Phosphomannomutase II Deficiency
    View official trial listing →
  • Status unknown NCT NCT05184049

    Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients

    Not yet reported Xiangya Hospital of Central South University 72 participants Est. completion 2023-10 1 site Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Status unknown NCT NCT05777226

    Research of SORD-CMT Natural History and Epalrestat Treatment

    Not yet reported The Third Xiangya Hospital of Central South University 30 participants Est. completion 2026-04 Stand-alone
    Other conditions: Charcot-Marie-Tooth Disease (CMT)
    View official trial listing →
  • Active, not recruiting NCT NCT06330233

    Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study

    Not yet reported Zhejiang Chinese Medical University 90 participants Est. completion 2026-12-31 3 sites Stand-alone
    Other conditions: Diabetic Peripheral Neuropathy, Pain, Moxibustion, Randomized Controlled Trial
    View official trial listing →
  • Not yet recruiting NCT NCT07557914

    Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

    Not yet reported Haibo Shao 32 participants Est. completion 2029-02 1 site Stand-alone
    Other conditions: HCC - Hepatocellular Carcinoma, Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.